Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HyperAcute vaccine
- Development stage
- Unknown
- Lead developer
- Lumos Pharma
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
The "HyperAcute vaccine" refers to a family of allogeneic whole-cell cancer vaccines developed by NewLink Genetics. These vaccines are genetically engineered tumor cell lines that express the murine alpha-galactosyl (alpha-gal) epitope on their surface. When injected into humans, these cells trigger a hyperacute rejection response mediated by pre-existing human anti-alpha-gal antibodies. This immune reaction leads to rapid destruction of the injected cells and stimulates an anti-tumor immune response against similar antigens present on the patient's own tumor cells. Each "HyperAcute" variant is tailored for a specific cancer type (e.g., pancreas, lung, prostate). The most well-known member is algenpantucel-L for pancreatic cancer[4][7][9].
- Other names
- algenpantucel-L (for pancreatic cancer variant)HyperAcute-PancreasHyperAcute-LungHyperAcute-Prostate
Beyond the preview
Go deeper on HyperAcute vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HyperAcute vaccine.